Emmaus Life Sciences has submitted an application seeking the approval of its oral medication Endari (L-glutamine) to treat…
Articles by Marisa Wexler, MS
A new research collaboration between Jasper Therapeutics and Aruvant Sciences will evaluate the use of JSP191, Jasper’s anti-CD117 monoclonal antibody,…
Bluebird Bio is set to resume trials of LentiGlobin, its investigational gene therapy for sickle cell disease, after…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
A spoken word poetry contest is welcoming submissions from people with sickle cell disease (SCD) and their caregivers. The…
LentiGlobin, Bluebird Bio’s investigational gene therapy for sickle cell disease (SCD), is unlikely to be the cause of…
Red blood cells in people with sickle cell disease (SCD) flow through blood vessels in a manner that damages…
The European Medicines Agency (EMA) is reviewing an application from Global Blood Therapeutics (GBT) that seeks full marketing approval…
FT-4202, a potential disease-modifying oral treatment for sickle cell disease (SCD), is well-tolerated in people with SCD and induces…
A team of researchers led by UNC Project-Malawi has been given a one-year, $500,000 grant to build clinical and…